Matchpoint Therapeutics Raises $150 Million Series B to Bring Oral T Cell Modulator Into the Clinic

What happened

Matchpoint Therapeutics, a preclinical biotech based in Watertown, Massachusetts, announced on Wednesday, Oct. 7, that it has raised $150 million in a Series B financing. According to BioSpace, the round was led by Swiss investor Nextech Invest and private equity firm Norwest, with participation from Sanofi Ventures, T1D Fund, Atlas Venture and Access Biotechnology, among others.

The company plans to use the money to advance its lead asset, MPT-062, into human trials.

Round and company details

• Amount: $150 million Series B.
• Leads: Nextech Invest and Norwest.
• Other investors: Sanofi Ventures, T1D Fund, Atlas Venture and Access Biotechnology, among others.
• Prior funding: A $100 million Series A in October 2022, led by Sanofi Ventures.
• Chief executive: Andre Turenne.

MPT-062 is an oral small-molecule T cell modulator designed to treat autoimmune and inflammatory diseases driven by overactive T cells. Clinical development is expected to begin in 2027, and Turenne describes the drug as potentially first-in-class.

Matchpoint’s ACE (Advanced Covalent Exploration) platform uses machine learning to design small molecules that bind disease proteins that have been difficult to target. Novartis paid $60 million upfront in July 2025 for access to the platform for oral inflammatory-disease medicines, in a deal that could bring up to $1 billion in milestones plus royalties, BioSpace reported.

Kanishka Pothula, managing partner at Nextech Invest, said MPT-062 has the “potential to precisely address the disease-causing overactivation of T cells.”

Why it matters for the sector

Autoimmune and inflammatory diseases are among the largest markets in pharma, and many of the most successful treatments are injectable biologics. Oral small molecules that act on the same pathways can be more convenient for patients and less expensive to manufacture, which is why drugmakers have invested heavily in oral immunology programs.

Covalent drugs, which form a lasting chemical bond with their target protein, can achieve strong and durable effects with small molecules. Advances in computational chemistry and machine learning have renewed interest in covalent approaches by helping developers design molecules that bind selectively and avoid unwanted reactions with other proteins.

The round is notable for its size at the preclinical stage. Investors have generally been more selective with early-stage companies in recent years, concentrating capital on programs with clinical data. A $150 million raise before human testing suggests confidence in the platform, reinforced by its existing Novartis partnership and continued backing from Sanofi Ventures.

The investor mix, which pairs a European biotech specialist with a growth-equity firm and corporate venture arms, is also typical of large private rounds in 2026, as companies seek both scientific credibility and financial depth.

For Sanofi Ventures, participating in both the Series A and Series B is a sign of continued conviction from a strategic investor. Corporate venture arms often invest in companies working in areas of interest to their parent, which can position the parent for future partnerships, though such investments do not guarantee a deal.

The financing also gives Matchpoint resources to run its first trials without immediately seeking additional capital, a factor that can strengthen its position in future partnership negotiations.

Clinical entry in 2027 will be the first test of whether the platform’s design advantages translate into human data.

What to watch

• Initiation of the first clinical trial of MPT-062, expected in 2027.
• Progress under the Novartis platform agreement, including any milestone payments.
• Additional partnerships for the ACE platform with other drugmakers.
• Competing oral T cell modulator programs from larger companies.

Sources: BioSpace

Covalent Drugs, Old and New

Most drugs bind their targets reversibly, attaching and detaching repeatedly. A covalent drug forms a chemical bond with its target, which can keep the target switched off until the cell makes a new copy of the protein.

The idea is not new. Aspirin works partly by permanently modifying an enzyme involved in inflammation and clotting, and penicillin binds bacterial enzymes covalently. For many years, though, drug developers were cautious about deliberately designing covalent drugs, worrying that reactive molecules might bind unintended proteins and cause toxicity.

That view has shifted. Targeted covalent drugs have been approved in cancer, including inhibitors of BTK and of the KRAS G12C mutant. These drugs pair a mildly reactive chemical group with a structure that fits a specific pocket, so the bond forms mainly where intended.

Where machine learning helps

• Identifying reactive amino acids, often cysteines, on proteins that might serve as anchor points.
• Predicting which molecules will bind selectively and which might react with other proteins.
• Prioritizing designs for synthesis and testing, reducing trial and error.

Why Overactive T Cells Matter in Autoimmunity

T cells coordinate and carry out much of the immune system’s targeted response. In autoimmune diseases, some T cells react against the body’s own tissues. Depending on the disease, overactive T cells may attack insulin-producing cells in the pancreas, as in type 1 diabetes, or drive inflammation in skin, joints or the gut. A modulator aims to calm that overactivation without broadly shutting down the immune system, which is a difficult balance.

From Preclinical to First-in-Human: The Usual Steps

1. Candidate selection. A lead molecule is chosen based on potency, selectivity and drug-like properties.
2. IND-enabling studies. Formal safety and toxicology studies are conducted, alongside work to manufacture the drug consistently.
3. Regulatory submission. An investigational new drug application is filed with the FDA, or an equivalent application elsewhere.
4. Phase 1. The first human studies, often in healthy volunteers for small molecules, evaluate safety, tolerability and how the drug moves through the body.
5. Patient studies. Later trials test whether the drug helps people with the target disease.

Questions Readers Ask

Why does a platform deal with Novartis matter for this round?

An outside partnership offers independent validation of the platform and brings in non-dilutive funding. Investors often view a pharma partner’s willingness to pay for platform access as evidence that the technology produces useful molecules.

What does “first-in-class” mean for a preclinical drug?

It describes an aspiration: that the drug would be the first approved medicine to work through its particular mechanism. Whether that happens depends on years of trials and on what competitors achieve in the meantime.

Why would a type 1 diabetes fund invest?

Type 1 diabetes is driven by T cells attacking insulin-producing cells, so therapies that calm overactive T cells are of natural interest to investors focused on that disease.

Are oral immunology drugs safer than injectables?

Not inherently. Safety depends on the specific drug and target. Patients should discuss treatment options with their own physicians.

This article is for general information only and is not medical or investment advice.